Odin Medical Ltd. (an Olympus Corporation company)

43-45 Foley Street, London, England, W1W 7TS, UK All United Kingdom companies → — Founded 2018

Imaging AI Specialist Specialty-Focused AI

Colorectal Surgery Gastroenterology Radiology

Clinical Decision Support & Reference Gastroenterology AI Radiology & Imaging AI

Acquired by Olympus Corporation — Up to £66 million (approx. $80 million)

Website Claim this company

Products

CADDIE™ Computer-Aided Detection (CADe) Device

Odin Medical Ltd. (an Olympus Corporation company)

Clinical Decision Support & Reference

CADDIE™ is the first cloud-based AI technology to receive FDA clearance, designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures. This AI tool, developed by Odin Medical Ltd., an Olympus Corporation company, supports real-time polyp detection and characterization, improves adenoma detection rates, and integrates seamlessly into existing clinical workflows.

Per procedure cost effectiveness

Odin CADDIE™

Odin Medical Ltd. (an Olympus Corporation company)

Gastroenterology AI

FDA-cleared cloud-based AI technology designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures.

N/a

See all 2 products →

About Odin Medical Ltd. (an Olympus Corporation company)

Odin Medical Ltd., operating as Odin Vision and an Olympus Corporation company, is a leading healthcare AI firm dedicated to advancing endoscopic procedures through innovative cloud-based artificial intelligence solutions. The company’s core mission is to empower physicians with cutting-edge tools that enhance the quality of patient care, improve clinical outcomes, and deliver greater value to healthcare providers.

Their flagship product, CADDIE™ (computer-aided detection and diagnosis for endoscopy), is a cloud-based AI device designed to assist gastroenterologists in the real-time detection and characterization of suspected colorectal polyps during colonoscopy procedures. By analyzing live video feeds and highlighting potential lesions, CADDIE™ aims to reduce the rate of missed polyps, which is crucial for the early detection and prevention of colorectal cancer. Odin Medical Ltd. also offers other specialized AI solutions, including CADU for analyzing dysplasia in Barrett’s Esophagus and SMARTIBD for assisting in the analysis of ulcerative colitis during colonoscopies.

These technologies are integral to Olympus’s broader digital strategy and Intelligent Endoscopy Ecosystem, focusing on transforming clinical workflows, strengthening clinical decision-making, and improving operational efficiencies within the endoscopy suite. By leveraging AI and cloud connectivity, Odin Medical Ltd. strives to provide scalable, updatable, and cost-effective solutions that support endoscopists in delivering a high standard of care to patients worldwide.

Focus Areas

Cloud AI endoscopy colorectal cancer detection polyp characterization Barrett's Esophagus dysplasia detection ulcerative colitis analysis

Business Intelligence

Key Investors	UCL Technology Fund, London Co-Investment Fund, AI Seed Fund, angel investors
Partnerships	Olympus Corporation (acquired by), University College London (UCL), NHS AI Lab, Accelerated Access Collaborative (AAC), National Institute for Health Research (NIHR), NVIDIA
Acquisitions	Acquired by Olympus Corporation on December 19, 2022
Technology	Cloud-based AI endoscopy system, real-time video analysis, machine learning algorithms, convolutional neural networks, integrated into clinical workflows, remotely updated software, part of Olympus's OLYSENSE™ platform
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Cloud AI Endoscopy Ecosystem

Odin Medical Ltd., an Olympus Corporation company (trading as Odin Vision), specializes in cloud-based AI endoscopy, integrating hardware, software, services, and data to enhance clinical outcomes and operational efficiency. Their solutions are part of Olympus's Intelligent Endoscopy Ecosystem, aiming to transform gastrointestinal care.

Colorectal Cancer Detection & Polyp Characterization (CADDIEu2122)

CADDIEu2122 is an AI-driven, cloud-based device that assists gastroenterologists in real-time detection and characterization of suspected colorectal polyps and potential early signs of colorectal cancer during colonoscopy procedures. It provides both computer-aided detection (CADe) and diagnosis (CADx) functions, analyzing video frames and highlighting suspicious areas.

Barrett's Esophagus Dysplasia Detection (CADU)

CADU is a cloud-based AI solution designed to aid in analyzing dysplasia in patients with Barrett's Esophagus during gastroscopy procedures, providing real-time data analysis for endoscopists.

Ulcerative Colitis Analysis (SMARTIBD)

SMARTIBD is an AI solution developed to assist clinicians in analyzing ulcerative colitis during colonoscopy procedures by processing colonoscopy video frames and offering real-time insights to characterize tissue.

Physician Tip

For physicians, Odin Medical's cloud-AI endoscopy solutions act as an 'expert second pair of eyes,' enhancing vigilance and potentially improving the detection rate of subtle or flat polyps and other abnormalities that might otherwise be overlooked, especially in high-volume screening environments. The real-time feedback allows for immediate action, supporting earlier diagnosis and better patient outcomes. The cloud-based nature ensures that the AI software can be remotely updated, providing continuous access to the latest advancements without requiring standalone hardware upgrades, thus ensuring access to current technology and potentially reducing operational burdens and costs. These systems are designed to integrate seamlessly into existing clinical workflows with minimal training, allowing clinicians to focus more on patient care. While the AI assists in detection, the ultimate clinical decision-making remains with the endoscopist.

Odin Medical's AI products are integrated within Olympus's OLYSENSEu2122 CAD/AI Intelligent Endoscopy Ecosystem. This platform operates during procedures, analyzing live video feeds and prompting clinicians to review highlighted areas of concern. The cloud-connected nature means the system can evolve via software updates, ensuring hospitals stay up-to-date with AI advancements.

At a glance

Founded 2018

HQ 43-45 Foley Street, London, England, W1W 7TS, UK · United Kingdom

Team size 60

CEO Peter Mountney, Ph.D.

Funding Acquired by Olympus Corporation — Up to £66 million (approx. $80 million)

FDA clearances 2 (estimated)

Products 2

Visit site

Products by Odin Medical Ltd. (an Olympus Corporation company)

2 products in the directory

CADDIE™ Computer-Aided Detection (CADe) Device

Odin Medical Ltd. (an Olympus Corporation company)

Clinical Decision Support & Reference

Per procedure cost effectiveness

Odin CADDIE™

Odin Medical Ltd. (an Olympus Corporation company)

Gastroenterology AI

FDA-cleared cloud-based AI technology designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures.

N/a

What the Web Says

Odin Medical Ltd., an Olympus Corporation company, specializes in cloud-based AI endoscopy solutions aimed at improving the detection of early signs of colorectal cancer and other gastrointestinal conditions. Their flagship product, CADDIE, a cloud-based AI system for colonoscopy, has received FDA 510(k) clearance and CE mark approval in Europe. The company's technology is designed to assist gastroenterologists in real-time by analyzing colonoscopy video and using visual markers to alert them to the potential presence of polyps, thereby enhancing detection capabilities and patient care. While specific reviews for Odin Medical Ltd. are limited, broader reviews for its parent company, Olympus Corporation, indicate a mixed but generally positive sentiment regarding its work environment and products.

Overall: Mixed

Strengths

CADDIE device improves adenoma detection rates per colonoscopy, linked to cancer prevention.
Cloud-based AI software allows for remote updates and offers flexibility, speed-to-innovation, and potential cost-savings for hospitals.
Products like CADDIE are user-friendly and integrate into clinical workflows.
Olympus (parent company) is recognized for great products and good leadership.
Olympus offers good benefits and work-life balance.
Olympus provides a good environment for learning and professional development.

Limitations

Some employees at Olympus (parent company) report a lack of communication between management and employees.
Work can become mundane or stale in some positions at Olympus.
Pay at Olympus is sometimes perceived as lower compared to other medical device companies.
There can be a lack of accountability in some groups within Olympus.
Some past Reddit discussions mention potential issues with Olympus's reputation due to lawsuits and product recalls, though this is not directly tied to Odin Medical.
Some former employees of Olympus's Urology/GI teams cited poor management decisions and low pay as reasons for leaving.

Based on reviews from: Indeed.com, Capterra, Reddit, Fortune Business Insights, Olympus (news releases), Odin Vision

Last updated: 2026-07-21

Videos

News, demos, and interviews about Odin Medical Ltd. (an Olympus Corporation company).

Loading videos...

Videos load interactively. If none appear, search YouTube for Odin Medical Ltd. (an Olympus Corporation company) →

View all on YouTube

Press & Coverage

Olympus

First Cloud-Based AI Endoscopy System for Colonoscopy Receives FDA Clearance

Odin Medical Ltd., an Olympus Corporation company, received U.S. FDA 510(k) clearance for CADDIEu2122, the first cloud-based AI technology to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures.

2024-09

Olympus Europa SE & Co. KG

Olympus Announces CE Approval for Three Cloud-based AI Medical Devices and Announces Plans for Launch of AI-Powered Endoscopy Ecosystem in 2025

Odin Medical Ltd. (Odin Vision), an Olympus group company, received CE mark approval for its cloud-AI endoscopy medical devices CADDIE, CADU, and SMARTIBD in Europe under the Medical Device Regulation (MDR).

2024-10

Surgical Robotics Technology

Odin Medical Ltd. Receives FDA 510(k) Clearance for Cloud-Based AI Endoscopy System

Odin Medical Ltd., an Olympus Corporation company, has been granted U.S. FDA 510(k) clearance for its CADDIEu2122 computer-aided detection (CADe) device, a cloud-based AI technology for detecting colorectal polyps during colonoscopies.

2024-09

Medical Product Outsourcing

Olympus' Odin Medical Gets FDA OK for 1st Cloud-Based AI Endoscopy Tech for Colonoscopy

Olympus Corporation's Odin Medical has received U.S. FDA 510(k) clearance for the CADDIE computer-aided detection device, the first cloud-based AI technology to assist gastroenterologists in identifying suspected colorectal polyps during colonoscopies.

2024-09

The Worldfolio

OLYSENSEu2122: Advancing Intelligent Endoscopy for a Healthier Future

The OLYSENSEu2122 platform, featuring Odin Medical Ltd.'s AI-powered CADDIEu2122 software, assists endoscopists in real-time detection of colorectal lesions, aiming to improve early cancer detection and patient care.

2025-11

Signalbase

Odin Vision Acquired by Olympus Corporation | M&A News - Signalbase

Olympus Corporation acquired Odin Vision, a company specializing in AI applications for endoscopic procedures, to enhance its portfolio in AI-driven medical technologies and improve early cancer detection and diagnosis.

2025-05

Olympus Corporation

Notice Regarding Acquisition of Odin Medical Ltd. (to make it a subsidiary) in the UK

Olympus Corporation announced the acquisition of all outstanding shares of Odin Medical Ltd., a cloud-AI endoscopy company, in December 2022, as a strategic step to enhance its digital strategy and improve patient care.

2022-12

MedTech Dive

Olympus agrees to $80M takeover of artificial intelligence endoscopy startup Odin Vision

Olympus acquired AI endoscopy startup Odin Vision for up to u00a366 million ($80 million), integrating Odin's cloud-based AI systems, Caddie and Cadu, to enhance the detection and characterization of cancerous tissues during endoscopic procedures.

2022-12

Frequently Asked Questions

What specific AI endoscopy products does Odin Medical Ltd. offer, and which clinical areas do they address?

Odin Medical Ltd., an Olympus Corporation company, offers cloud-based AI solutions including CADDIEu2122 for real-time detection and characterization of colorectal polyps during colonoscopy, and CADUu2122 for analyzing dysplasia in Barrett's Esophagus during gastroscopy. They also provide SMARTIBDu2122 for real-time analysis of ulcerative colitis during colonoscopy procedures.

How does Odin Medical's cloud-based AI approach benefit our endoscopy unit in terms of technology, updates, and workflow?

Odin Medical's cloud-based AI systems, such as CADDIEu2122, offer remote software updates, ensuring your unit always has access to the latest AI advancements. This approach provides flexibility, speed-to-innovation, and potential cost-savings by avoiding the need for expensive, standalone hardware upgrades.

What regulatory clearances do Odin Medical's AI endoscopy products currently hold for market use?

Odin Medical's CADDIEu2122 device has received U.S. Food and Drug Administration (FDA) 510(k) clearance, making it the first cloud-based AI endoscopy system for colonoscopy cleared in the US. Additionally, CADDIEu2122, CADUu2122, and SMARTIBDu2122 have all received CE Mark approval under the Medical Device Regulation (MDR) in Europe.

How do Odin Medical's AI systems integrate with existing endoscopy equipment, and what kind of support and training are provided?

Odin Medical's AI systems are designed to integrate seamlessly with existing endoscopy equipment, typically connecting via a small computer to the endoscopy stack to stream video to the cloud for analysis. The intuitive nature of their solutions, like CADUu2122, means minimal training is required, and as an Olympus company, robust support is expected as part of their Intelligent Endoscopy Ecosystem.

As an Olympus Corporation company, how does this acquisition impact Odin Medical's long-term stability and product development roadmap?

Odin Medical Ltd. was acquired by Olympus Corporation in December 2022, providing significant long-term stability and strategic backing from a global medical technology leader. This acquisition positions Odin as Olympus' first Digital Excellence Center, accelerating the development and global adoption of their AI solutions within Olympus' broader digital strategy for endoscopy.

What is the general pricing model for Odin Medical's AI endoscopy solutions, and what are the potential cost-savings for healthcare institutions?

While specific pricing details are not publicly disclosed, the cloud-based nature of Odin Medical's AI solutions suggests a model that could offer flexibility, potentially through subscriptions or per-use arrangements. This cloud infrastructure is designed to provide potential cost-savings by eliminating the need for hospitals to invest in and maintain expensive, rapidly aging on-premise hardware.

What clinical evidence supports the efficacy of Odin Medical's AI solutions in improving detection and diagnosis?

The CADDIEu2122 device, for instance, has demonstrated efficacy and safety in a prospective, multi-center randomized controlled trial conducted across eight medical centers in Europe, showing improved adenoma detection per colonoscopy. This evidence underscores its potential to enhance detection capabilities and patient care without increasing procedural risks or duration.

Related Companies

Suggest an Edit →